Dibazol-Darnitsa

General characteristics. Structure:

Active ingredient: bendazol;

1 ml of solution contains Bendazolum of a hydrochloride 10 mg;

excipients: ethanol of 96%, glycerin, Acidum hydrochloricum, water for injections.

Pharmacological properties:

Pharmacodynamics. Vazodilatiruyushchy and antispasmodic. Possesses hypotensive, vasodilating action, stimulates function of a spinal cord, has the moderate immunostimulating activity.

Has direct spasmolytic effect on unstriated muscles of blood vessels and internals. Drug causes short (2-3 hours) and the moderate hypotensive effect, is well transferred. Causes short expansion of brain vessels at the chronic hypoxia of a brain caused by local disturbance of blood circulation (a sclerosis of cerebral arteries). Facilitates synoptic transfer in a spinal cord. Has immunomodulatory activity. Due to regulation of a ratio of concentration of tsGMF and tsAMF in immune cells increases the maintenance of tsGMF that leads to proliferation of mature sensibilized T-and B-lymphocytes, secretion by them of factors of mutual regulation, cooperative reaction and activation of final effector function of cells. Drug stimulates products of antibodies, increases phagocytal activity of leukocytes, macrophages, improves interferon synthesis, but the immunomodulatory effect develops slowly.

Pharmacokinetics. At intramuscular introduction drug quickly gets into a system blood stream. The maximum concentration in blood is observed in 15-30 minutes from the moment of introduction. Action duration – 2-3 hours. It is metabolized in a liver.

Products of biotransformation of Dibazolum are two conjugates which are formed owing to methylation and a karboetoksilirovaniye of iminogroup of an imidazolny ring of Dibazolum: 1-methyl-2-benzylbenzimidazole and 1-karboetoks-2 benzylbenzimidazole.

Products of metabolism are excreted preferential with urine.

Pharmaceutical characteristics.

Main physical and chemical properties: transparent colourless or with slightly yellowish or greenish shade liquid.

Incompatibility. Dibazolum is incompatible with salicylates and benzoates as there is a loss of a deposit of salicylate or benzoate of Dibazolum.

Indications to use:

As an additional tool at spasms of blood vessels (an exacerbation of a hypertension, hypertensive crises) and unstriated muscles of internals (spasms of a pylorus of a stomach, intestines); at treatment of nervous diseases (mainly, the residual phenomena of poliomyelitis, a flaccid paralysis of a facial nerve, a polyneuritis).

Route of administration and doses:

To adults and children 12 years are more senior Dibazol-Darnitsa appoint intravenously, intramusculary or subcutaneously. For stopping of hypertensive crises enter intravenously or intramusculary 3-5 ml of 1% of solution (30-50 mg). At substantial increase of arterial pressure intramuscular introduction on 2-3 ml of 1% of drug (20-30 mg) 2-3 times a day is shown. The course of treatment is appointed individually, on average 8-14 days.

Features of use:

Use during pregnancy or feeding by a breast.

Not to use drug during pregnancy or feeding by a breast.

Children.

Drug is not appointed to children aged up to 12 years.

Before an initiation of treatment consult to the doctor!

Dibazolum in the form of injections is supportive application which is used at arterial hypertension on condition of sensitivity to other antihypertensives. At treatment of arterial hypertension it is recommended to combine with other hypotensive drugs.

Prolonged use of Dibazola-Darnitsa as anti-hypertensive means at patients of senile age because of a possibility of deterioration in indicators of an ECG, reduction of cordial emission is inexpedient.

It is not recommended to apply to prolonged treatment of arterial hypertension, especially to patients of advanced age.

Ability to influence speed of response at control of motor transport or work with other mechanisms.

During treatment it is necessary to be careful at control of vehicles and work with difficult mechanisms, and in case of developing of dizziness to refrain from work with potentially dangerous types of activity which demand the increased concentration of attention and speed of psychomotor reactions.

Side effects:

from the central and peripheral nervous system: dizziness, headache;

from cardiovascular system: a heart consciousness, pain in heart, at prolonged use – deterioration in indicators of an ECG in connection with reduction of cordial emission; lowering of arterial pressure;

from respiratory system: dry cough, cold, the complicated breath;

from the alimentary system: nausea, burning in a throat;

from immune system: itch, hyperemia, rashes, urticaria;

general disturbances: feeling of heat, the increased sweating, face reddening.

reactions in an injection site: local morbidity.

Interaction with other medicines:

If you accept any other medicines, surely consult with the doctor concerning a possibility of use of drug.

Papaverine the hydrochloride, theobromine, Salsolinum – at the combined use with Dibazolum extends a range of pharmacological action of a papaverine of a hydrochloride, theobromine, Salsolinum.

Barbiturates – at the combined use with Dibazolum efficiency of barbiturates of long action, in particular phenobarbital amplifies.

Phentolamine, hypotensive drugs (the means influencing a renin-angiotenzinovuyu system, etc.), saluretics – at the combined use with Dibazolum amplifies hypotensive effect.

β-blockers - - - - - - - - - – at the combined use about dibazolomgipotenzivny effect of the last does not change, but at prolonged use Dibazolum prevents increase in the general peripheric resistance caused by β-blockers..........

Contraindications:

Hypersensitivity to drug. The diseases proceeding with decrease in a muscle tone, a convulsive syndrome, heavy heart failure. Hypotension. Chronic nephrite with hypostases and disturbance of azotovydelitelny function of kidneys. Stomach ulcer and a duodenum with bleeding. Diabetes mellitus.

Overdose:

Symptoms: hypotension, perspiration, feeling of heat, dizziness, nausea, a slight headache which quickly pass at drug withdrawal.

Treatment. To cancel drug. At the expressed hypotension under control of the ABP appoint transfusion therapy, vasoconstrictors, cardiac glycosides. Symptomatic further treatment.

Storage conditions:

Period of validity 4 years. To store in the place, unavailable to children, in original packaging at a temperature not above 25 °C. Not to freeze.

Issue conditions:

According to the recipe

Packaging:

On 1 ml or 5 ml in an ampoule; on 5 ampoules in a blister strip packaging; on the 2nd blister strip packagings in a pack; on 10 ampoules in a box.